Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
AstraZeneca
Sotio Biotech Inc.
Erasca, Inc.
Kaiser Permanente
Sichuan Enray Pharmaceutical Sciences Company
Arvinas Inc.
Jonsson Comprehensive Cancer Center
University of Colorado, Denver
xCures
Fred Hutchinson Cancer Center
University of Nebraska
Zhejiang University
Adela, Inc
Eli Lilly and Company
RenJi Hospital
Degron Therapeutics Co.
National Cancer Institute (NCI)
Bayer
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Ikena Oncology
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Azienda Ospedaliera di Padova
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Columbia University